FindTrial
Sign In

ABBV-951

DRUG7 trials

Sponsors

AbbVie

Conditions

Parkinson's DiseaseParkinson's Disease (PD)

Phase 1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
CompletedNCT03033498
AbbVieParkinson's Disease (PD)
Start: 2017-05-17End: 2019-06-08Updated: 2024-11-12
A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
CompletedNCT03374917
AbbVieParkinson's Disease (PD)
Start: 2018-04-18End: 2019-03-04Updated: 2024-11-12
Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease
CompletedNCT05094050
AbbVieParkinson's Disease
Start: 2022-01-18End: 2023-03-17Updated: 2023-03-24

Phase 3

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)
CompletedNCT03781167
AbbVieParkinson's Disease (PD)
Start: 2019-04-29End: 2022-08-17Updated: 2023-10-23
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
CompletedNCT04379050
AbbVieParkinson's Disease (PD)
Start: 2020-06-08End: 2026-04-17Updated: 2026-05-13
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
CompletedNCT04380142
AbbVieParkinson's Disease (PD)
Start: 2020-10-19End: 2021-09-29Updated: 2022-11-18
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
CompletedNCT04750226
AbbVieParkinson's Disease (PD)
Start: 2021-02-18End: 2026-04-27Updated: 2026-06-01

Related Papers

Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results
Neurology and Therapy2026-05-07
Foslevodopa/Foscarbidopa Subcutaneous Infusion Safety and Efficacy in Patients with and Without Prior Deep Brain Stimulation.
2026-04-15
Foslevodopa/Foscarbidopa in Younger Patients Earlier Within Advanced Parkinson's Disease: Post Hoc Analysis of a Randomized Trial.
2025-12-01
Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials.
2025-10-04
Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease
Movement Disorders Clinical Practice2025-07-304 citations
Licensed Subcutaneous Infusion Therapies in Advanced Parkinson's Disease: An Indirect Treatment Comparison and Cost-Minimisation Analysis.
2025-07-081 citations
Bioequivalence of Foslevodopa/Foscarbidopa continuous subcutaneous infusion to arm, thigh, or flank versus abdomen in healthy and advanced Parkinson's disease individuals.
2025-06-141 citations
Patients’ experience with and perspectives on long-term use of continuous subcutaneous infusion of foslevodopa/foscarbidopa in Parkinson’s disease
Journal of Neurology2025-05-221 citations
Post hoc exploratory analysis of the effect of foslevodopa/foscarbidopa continuous subcutaneous infusion on nocturia in patients with Parkinson's disease.
2025-04-26
Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa
Movement Disorders Clinical Practice2024-03-1117 citations
Rapid good ON-time-onset and motor symptom improvement in aPD patients treated with subcutaneous foslevodopa/foscarbidopa
2023-11-01
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Neurology and Therapy2023-08-2690 citations
Safety of Foslevodopa/Foscarbidopa During Optimization and Maintenance Treatment: Post Hoc Analysis of a Phase 3 Trial (S32.004)
Neurology2023-04-253 citations
Characterizing a Parkinson’s Disease Population Inadequately Controlled by Oral Therapy: Baseline Characteristics of the Phase 3 Clinical Program for Foslevodopa/Foscarbidopa (P2-11.006)
Neurology2023-04-25
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
2022-12-01108 citations